New study tests if MRI-Guided radiation reduces side effects in prostate cancer

NCT ID NCT04384770

Ongoing Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase III trial compares two types of image-guided radiation for prostate cancer: CT-guided and MRI-guided stereotactic body radiotherapy (SBRT). About 179 men with localized prostate cancer will receive the same radiation dose, but one group's treatment is guided by CT scans and the other by MRI scans. The main goal is to see if MRI guidance causes fewer urinary and bowel side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (stereotactic body radiotherapy, SBRT)
What this could lead to: If MRI guidance proves better, it could become the new standard for prostate cancer radiation, reducing urinary and bowel side effects.
What could go wrong: This is a mid-stage trial with 179 participants, so results may not apply to all patients. MRI guidance may not significantly improve outcomes over CT.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.